HomeInsightsStock Comparison

Novartis India Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Novartis India Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jun 28, 2025

Key Highlights

  • The Latest Trading Price of Novartis India Ltd is ₹ 1002 as of 27 Jun 15:30.
  • The P/E Ratio of Novartis India Ltd is 0 as of March 2022 .The P/E Ratio of Senores Pharmaceuticals Ltd is 0 as of March 2022.
  • The Market Cap of Novartis India Ltd is ₹ 0 crore as of March 2022 .The Market Cap of Senores Pharmaceuticals Ltd is ₹ 0 crore as of March 2022.
  • The revenue of Novartis India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Senores Pharmaceuticals Ltd for the Mar '25 is ₹ 125.98 crore as compare to the Dec '24 revenue of ₹ 108.18 crore. This represent the growth of 16.45%.
  • The ebitda of Novartis India Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Senores Pharmaceuticals Ltd for the Mar '25 is ₹ 31.21 crore as compare to the Dec '24 ebitda of ₹ 30.85 crore. This represent the growth of 1.17%.
  • The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 7.11 crore to ₹ 17.97 crore over 4 quarters. This represents a CAGR of 152.74% .
  • The Dividend Payout of Novartis India Ltd changed from 244.84 % on March 2020 to 72.43 % on March 2024 . This represents a CAGR of -21.62% over 5 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Novartis India Ltd

  • Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
  • The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
  • The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
  • In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
  • In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

About Senores Pharmaceuticals Ltd

  • Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
  • Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
  • The Regulated Markets business is focused on Regulated Markets of US and Canada.
  • The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

Novartis India Ltd News Hub

News

Novartis India schedules AGM

Novartis India announced that the 77th Annual General Meeting(AGM) of the company will be ...

Read more

10 May 2025 09:38

News

Board of Novartis India recommends final dividend

Novartis India announced that the Board of Directors of the Company at its meeting held on...

Read more

10 May 2025 09:38

News

Novartis India to announce Quarterly Result

Novartis India will hold a meeting of the Board of Directors of the Company on 9 May 2025....

Read more

28 Mar 2025 09:32

News

Novartis India to hold board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 28 January ...

Read more

28 Dec 2024 09:37

News

Novartis India schedules board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 25 October ...

Read more

28 Sep 2024 10:07

News

Novartis India to declare Quarterly Result

Novartis India will hold a meeting of the Board of Directors of the Company on 29 July 202...

Read more

28 Jun 2024 17:50

Senores Pharmaceuticals Ltd News Hub

News

Senores Pharmaceuticals to hold board meeting

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 15...

Read more

10 May 2025 11:12

News

Senores Pharmaceuticals Inc. to acquire USFDA approved ANDA for Tramadol Tablets

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

09 May 2025 09:29

News

Senores Pharmaceuticals gains on acquiring Topiramate tablets from Wockhardt

Shares of Wockhardt declined 2.15% to Rs 1,267 on the BSE. The market size of Topiramate t...

Read more

06 May 2025 10:51

News

Senores inks deal to acquire Wockhardt's ANDA for Topiramate

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

05 May 2025 18:55

News

Senores Pharmaceuticals to acquire 14 ANDAs from Dr Reddy's

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

04 Mar 2025 14:23

News

Senores Pharma jumps on inking pact to acquire 14 ANDAs from Dr. Reddy's Labs

According to an exchange filing, the basket of acquired ANDAs consists of 13 USFDA-approve...

Read more

04 Mar 2025 15:35

SWOT Analysis Of Novartis India Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Novartis India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Novartis India Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, Novartis India Ltd or Senores Pharmaceuticals Ltd?

Market cap of Novartis India Ltd is 2,476 Cr while Market cap of Senores Pharmaceuticals Ltd is 2,615 Cr

What are the key factors driving the stock performance of Novartis India Ltd and Senores Pharmaceuticals Ltd?

The stock performance of Novartis India Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novartis India Ltd and Senores Pharmaceuticals Ltd?

As of June 28, 2025, the Novartis India Ltd stock price is INR ₹1002.9. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹567.9.

How do dividend payouts of Novartis India Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of Novartis India Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions